The FDA Removed the Black Box Warning From Hormone Therapy — Except the Part Most Coverage Left Out

On 10 November 2025 the US Department of Health and Human Services and the FDA announced they were initiating removal of the boxed warnings that have sat on menopausal hormone therapy labels since the mid-2000s. The warnings coming off relate to cardiovascular disease, breast cancer and probable dementia. One boxed warning is staying: endometrial cancer, on systemic estrogen-alone products.[1]

Most coverage reported the first sentence. The second sentence is the one that changes what a woman with a uterus should actually do.

What a boxed warning is

A boxed warning — the "black box" — is the strongest warning the FDA can require on a prescription label. It is not a footnote in the prescribing information; it sits at the top, framed, and it shapes how clinicians prescribe, how pharmacists counsel, and how insurers behave.

Its practical effect is often larger than its literal content. A boxed warning tells a busy prescriber this is the dangerous one, and that signal persists long after the evidence behind it has been re-examined.

Why the warnings were there

They came from the Women's Health Initiative, the large trials whose initial results were published in the early 2000s and stopped hormone therapy prescribing worldwide almost overnight.

The FDA's own framing of the 2025 decision notes that the boxed warnings were applied following a WHI study that found a statistically non-significant increase in certain risks.[1] That is a striking sentence to find in a regulator's announcement, and it is the crux of the reversal: a warning at the top of every label, for two decades, resting partly on a finding that did not reach statistical significance.

The fuller account of what the WHI found, what its later analyses complicate, and what its eighteen-year follow-up showed is in the trial that stopped hormone therapy — including the parts that do not flatter either side of the argument.

What is being removed

Per the FDA, the agency is working with manufacturers to update labelling to remove references to the risks of:

• cardiovascular disease
• breast cancer
• probable dementia[1]

What is staying, and why it matters

The FDA is not seeking to remove the boxed warning for endometrial cancer on systemic estrogen-alone products.[1]

That exception is not a technicality. Unopposed estrogen — estrogen given without a progestogen — stimulates the endometrium, and sustained stimulation raises the risk of endometrial hyperplasia and cancer. It is one of the better-established causal relationships in menopause medicine, and nothing in the 2025 decision disturbs it.

The practical translation is old advice, unchanged:

• A woman with a uterus taking systemic estrogen needs endometrial protection — a progestogen, on an appropriate regimen. Which regimens actually deliver it, and which route does not, is set out in why estrogen comes with progesterone.
• A woman who has had a hysterectomy does not face this particular risk, which is why estrogen-alone therapy exists as a category at all.
• Low-dose vaginal estrogen is a different question. Position-statement guidance is that a progestogen is not indicated with low-dose vaginal estrogen, though endometrial safety has not been studied in trials beyond a year — covered in vaginal estrogen for genitourinary symptoms.

Anyone reading the headline as "hormone therapy no longer carries a black box warning" will get this wrong, and the group they will get it wrong for is exactly the group the remaining warning protects.

What the change does and does not mean

It does not mean new evidence arrived. No trial reported in November 2025 that changed the picture. What changed is the regulator's reading of evidence that has been accumulating — including the extended WHI follow-up showing risk profiles differ substantially by age at initiation and time since menopause.

It does not mean hormone therapy is risk-free. Removing a boxed warning removes the framing of a risk as the label's headline danger. Risks that are real remain in the prescribing information and remain part of an individual conversation.

It does not change who should take it. The indications are unchanged: what hormone therapy actually treats is the same list it was before the announcement.

What it does change is the starting posture of the conversation. For two decades a boxed warning made hormone therapy something to be justified. That framing kept treatment from women whose symptoms warranted it and whose risk profile was favourable.

The other announcements

Alongside the labelling action, the FDA approved additional treatment options for menopausal symptoms, including a generic version of conjugated estrogens — the first such approval in more than thirty years.[1]

Timing

The changes were described as being implemented over roughly six months, with labels rewritten to carry age-specific guidance. A label change is not instantaneous, so during the transition some products will carry the old boxed warning and some the new language, and a package insert in hand may not reflect the current regulatory position.

Bottom line

The FDA is removing boxed warnings on menopausal hormone therapy for cardiovascular disease, breast cancer and probable dementia, on the basis that the original warnings overstated what the evidence supported. It is keeping the endometrial cancer boxed warning on systemic estrogen-alone products. If you have a uterus and take systemic estrogen, you still need endometrial protection — that requirement did not change on 10 November 2025, and reporting that says the black box warning was removed, full stop, is describing only part of what happened.

References

1 source

1. U.S. Department of Health and Human Services; U.S. Food and Drug Administration. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10, 2025. fda.gov